Dr. Sokolove brings more than 18 years of experience leading clinical development and translational research in autoimmune and inflammatory diseases across biotechnology and pharmaceutical organizations.
Prior to joining Vor Bio, Dr. Sokolove was Chief Medical Officer In-Residence at Roivant Sciences, where he led strategic assessment and in-licensing of novel therapeutic programs and provided clinical and operational leadership across Roivant’s portfolio companies. Previously, he served as Chief Medical Officer at Odyssey Therapeutics, guiding the company’s transition to a clinical-stage organization developing next-generation immunomodulators for autoimmune and inflammatory diseases.
Earlier in his career, Dr. Sokolove held senior leadership positions at GlaxoSmithKline as Senior Vice President and Head of Clinical Pharmacology & Experimental Medicine, and at AbbVie as Head of Immunology Translational Science, where he established portfolio-wide translation strategies, led registrational studies of upadacitinib (RINVOQ) in rheumatoid arthritis and giant cell arteritis, as well as Phase 2 combination studies of a novel JAK/BTK combination in rheumatoid arthritis and lupus.
An accomplished physician-scientist and rheumatologist, Dr. Sokolove was previously on the faculty at Stanford University Medical Center, has authored more than 90 peer-reviewed publications, and has served on editorial boards of leading medical journals.
Dr. Sokolove earned his MD from Boston University School of Medicine and completed his Internal Medicine residency at Boston University Medical Center, where he served as Chief Medical Resident. He completed clinical and research fellowships in Rheumatology and Immunology at Stanford University.